MAI Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

MAI Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.5M	Buy	86,701 +4,869	+6%	+$837K	0.06%	243
2026 Q1	$13.8M	Buy	81,832 +1,371	+2%	+$234K	0.08%	224
2025 Q4	$13.6M	Buy	80,461 +4,080	+5%	+$663K	0.08%	219
2025 Q3	$11M	Buy	76,381 +6,035	+9%	+$824K	0.07%	235
2025 Q2	$8.9M	Sell	70,346 -27,812	-28%	-$3.41M	0.06%	254
2025 Q1	$12.6M	Buy	98,158 +3,923	+4%	+$532K	0.09%	189
2024 Q4	$12.5M	Buy	94,235 +4,833	+5%	+$679K	0.09%	182
2024 Q3	$13M	Sell	89,402 -1,081	-1%	-$156K	0.12%	132
2024 Q2	$12.4M	Buy	90,483 +33,844	+60%	+$4.52M	0.12%	133
2024 Q1	$7.77M	Sell	56,639 -924	-2%	-$126K	0.08%	196
2023 Q4	$7.82M	Sell	57,563 -6,679	-10%	-$815K	0.1%	161
2023 Q3	$7.86M	Sell	64,242 -1,471	-2%	-$187K	0.12%	155
2023 Q2	$8.34M	Sell	65,713 -2,171	-3%	-$282K	0.12%	148
2023 Q1	$8.77M	Buy	67,884 +1,054	+2%	+$138K	0.14%	139
2022 Q4	$8.77M	Buy	66,830 +2,776	+4%	+$359K	0.15%	132
2022 Q3	$7.49M	Buy	64,054 +6,535	+11%	+$812K	0.14%	139
2022 Q2	$6.77M	Buy	57,519 +17,160	+43%	+$2.04M	0.13%	135
2022 Q1	$5.26M	Sell	40,359 -5,503	-12%	-$717K	0.09%	165
2021 Q4	$7M	Buy	45,862 +32,221	+236%	+$4.99M	0.11%	147
2021 Q3	$2.21M	Buy	13,641 +10,511	+336%	+$1.77M	0.04%	217
2021 Q2	$512K	Buy	3,130 +246	+9%	+$37.9K	0.01%	486
2021 Q1	$434K	Buy	2,884 +765	+36%	+$122K	0.01%	498
2020 Q4	$321K	Sell	2,119 -20	-0.9%	-$2.86K	0.01%	529
2020 Q3	$290K	Buy	2,139 +22	+1%	+$2.98K	0.01%	479
2020 Q2	$289K	Buy	+2,117	New	+$270K	0.01%	461
2018 Q1	–	Sell	-3,186	Closed	-$340K	–	478
2017 Q4	$340K	Buy	3,186 +78	+3%	+$8.34K	0.02%	333
2017 Q3	$346K	Buy	3,108 +90	+3%	+$9.62K	0.02%	313
2017 Q2	$312K	Hold	3,018	–	–	0.02%	337
2017 Q1	$295K	Sell	3,018 -10,152	-77%	-$972K	0.02%	340
2016 Q4	$1.17M	Buy	13,170 +3,342	+34%	+$304K	0.08%	168
2016 Q3	$948K	Buy	9,828 +282	+3%	+$26.8K	0.07%	183
2016 Q2	$819K	Buy	9,546 +120	+1%	+$10.8K	0.06%	204
2016 Q1	$819K	Buy	9,426 +930	+11%	+$83.2K	0.06%	204
2015 Q4	$958K	Buy	8,496 +435	+5%	+$47.2K	0.07%	180
2015 Q3	$815K	Buy	8,061 +2,907	+56%	+$349K	0.06%	217
2015 Q2	$634K	Buy	+5,154	New	+$617K	0.04%	272

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

MAI Capital Management's IBB Position: Q2 2026 in Review

MAI Capital Management increased its iShares Biotechnology ETF (IBB) stake by 5.9% in Q2 2026, buying an estimated $837K and bringing the position to 86,701 shares worth $16.5M. The position accounts for 0.06% of the portfolio, ranked #243.

MAI Capital Management first reported a position in IBB in Q2 2015 and has held it in 36 quarters since. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

MAI Capital Management held 86,701 shares of iShares Biotechnology ETF worth $16.5M as of Q2 2026.
MAI Capital Management bought 4,869 iShares Biotechnology ETF shares in Q2 2026, an estimated $837K.
iShares Biotechnology ETF made up 0.06% of MAI Capital Management's portfolio in Q2 2026, its #243 holding.
MAI Capital Management first reported a position in iShares Biotechnology ETF in Q2 2015 and has held it in 36 quarters since.
954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.